# Nectome **Entity class:** Concept or analytic term **Type:** Brain preservation company **Collection:** [[collections/Neurotech|Neurotech]] **Primary source:** [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] ## Definition Nectome is identified as a company that pursued commercialization of aldehyde-based brain preservation. ## Relationships [[wiki/Nectome|Nectome]] is related to [[wiki/Aldehyde-Stabilized Cryopreservation|ASC]] through attempted commercialization; preservation of structure is not demonstrated continuity of memory or personhood. <!-- BEGIN HUMANIZED RELATIONSHIPS 2026-09-11 --> This entry's documented connections are expressed in its definition and related-work routes, with provenance retained in the source-linked material. <!-- END HUMANIZED RELATIONSHIPS 2026-09-11 --> ## Source route [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]] · [[collections/Neurotech|Neurotech]] ## Related Work in the Corpus <!-- BEGIN HUMANIZED CORPUS ROUTES 2026-09-11 --> - In [[articles/2026 Annual Report on Brain-Computer Interfaces|2026 Annual Report on Brain-Computer Interfaces]], **Aldehyde-Stabilized Cryopreservation and Revival Pathways** provides the narrative context for **Nectome**: The Brain Preservation Foundation's 2018 Large Mammal Prize validated Aldehyde-Stabilized Cryopreservation (ASC) by 21st Century Medicine: glutaraldehyde fixation combined with ethylene glycol cryoprotectant perfusion and… <!-- END HUMANIZED CORPUS ROUTES 2026-09-11 -->